BPC-157 Evidence and Safety: What Human Research Shows

BPC-157 has a large body of animal research and almost no human research. The few human reports are small, uncontrolled and short on safety data. The FDA has not approved it, and it is prohibited in tested sports. Anyone considering a peptide should ask who prescribes it, which licensed pharmacy compounds it, and what human evidence supports the specific use. A product sold online as a “research chemical” can answer none of those questions.
This article covers what BPC-157 is, what has been tested in people, what the FDA and anti-doping bodies have said, and how provider-supervised care differs from buying unregulated peptides.
VivoChoose Peptide Care With Medical OversightVivo offers provider-supervised, personalized treatment selection and therapies prepared by licensed U.S. pharmacies, with care guided by your health history.VisitTL;DR
- BPC-157 is a synthetic 15-amino-acid peptide. Reported healing effects come mainly from animal studies.
- A 2026 systematic review found only three poor-quality, uncontrolled human studies with 30 participants in total.
- The FDA has proposed that BPC-157 not be added to the 503A Bulks List, and it is prohibited by WADA at all times.
- Products from research-chemical vendors carry unknown purity, dose and contamination risk. Licensed pharmacy preparation under provider supervision addresses those questions.
- Safety depends on the specific compound, route, dose, source and the person’s health history, which a licensed provider reviews.
Table of Contents
- What BPC-157 is and why it draws attention
- Animal evidence versus human evidence
- What the 2026 human evidence reviews conclude
- What the FDA has said
- Safety: what is known and what is not
- Tested athletes and servicemembers
- Why the source and the prescriber matter
- Our perspective
- A supervised route with Vivo
- Questions to ask any provider about a peptide
- FAQ
- Sources
What BPC-157 is and why it draws attention
BPC-157 is a synthetic pentadecapeptide, meaning a chain of 15 amino acids, with the sequence GEPPPGKPADDAGLV and a molecular mass of about 1,419 daltons. It was first isolated from human gastric juice in 1991, and animal models have reported regenerative and reparative properties across several tissues.

The interest comes from that animal work. According to AOSSM Sports Medicine News, animal models associate BPC-157 with increased blood vessel formation, changes in nitric oxide signaling, better fibroblast migration and more organized collagen deposition. Those are laboratory findings in animals, and they are not proof of a result in a person.
Animal evidence versus human evidence
The distinction matters more here than for almost any other peptide.
| Evidence type | What exists for BPC-157 | What it can tell you |
|---|---|---|
| Preclinical (cells, rodents) | Many studies, mostly tendon, muscle, nerve and gut models | Biological plausibility, not human benefit |
| Human clinical | A handful of small, uncontrolled reports | Early signals only |
| Human randomized trials | None identified in the reviews cited here | Needed to establish efficacy and safety |
A July 2025 systematic review in PubMed Central identified 36 studies, 35 of them preclinical and one clinical. The single clinical study was a retrospective case series. Seven of 12 patients with chronic knee pain reported relief lasting more than six months after an intra-articular injection of BPC-157. A retrospective case series looks back at patients who were already treated. It has no comparison group, so it cannot separate the effect of the peptide from natural recovery or the placebo response.
The review also reported that BPC-157 is metabolized in the liver with a half-life under 30 minutes and cleared by the kidneys, and that it found no clinical safety data.
What the 2026 human evidence reviews conclude
A systematic review by Poolton, Minett and Kazmi in 2026 included three poor-quality, uncontrolled human studies with 30 participants: one on knee pain, one on interstitial cystitis (a chronic bladder condition) and one intravenous safety study. Seven of 12 knee-pain patients reported relief for more than six months, and no drug-related adverse events were reported. With so few participants and no control groups, an absence of reported adverse events cannot establish safety.
An October 2026 narrative review in orthopaedics found the human musculoskeletal evidence limited to one small retrospective case series without validated outcome measures. It also found no validated dosing, pharmacokinetic or long-term safety data, and no FDA-approved musculoskeletal indication.
The American Association of Nurse Anesthesiology reported in July 2026 that human evidence is limited to small reports: intra-articular injections, bladder and gastrointestinal applications, and intravenous use in a two-patient series. A registered Phase I trial of BPC-157 safety and pharmacokinetics in healthy volunteers was terminated without published results.
For readers who want to see how a small uncontrolled series compares with the standard of evidence used in other injection-based treatments, this guide to evidence-first stem cell therapy shows how outcomes are usually judged.
What this means for specific injuries
People often ask whether BPC-157 can be used for a tendon injury or a labral injury such as a SLAP tear (a tear at the top of the shoulder socket). The published human evidence does not test BPC-157 for either. Professional bodies are direct on this point: the AANA advises that BPC-157 and similar research peptides cannot be recommended for wound healing, muscle growth, injury recovery or performance without clinical evidence. An orthopaedic or sports medicine clinician who has examined the injury is the right person to discuss it.
What the FDA has said
BPC-157 is not an FDA-approved drug. As of June 2026, the Poolton review verified that it is unapproved for human use by the FDA, the EMA and the MHRA (the European and UK regulators).
The more recent development concerns compounding. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy compounds a medication for an individual patient from a prescription. Bulk substances used this way generally need to meet criteria, and the FDA keeps a “503A Bulks List” of substances that qualify. For its July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting, the FDA’s briefing document stated that BPC-157 free base and BPC-157 acetate had been nominated for ulcerative colitis, and that the nominations were later withdrawn. The agency proceeded anyway and proposed that neither substance be included. Its reasons were that the substances are not well characterized, have limited historical compounding use, lack safety and immunogenicity information (whether the immune system may react to them), and have insufficient effectiveness evidence when approved ulcerative colitis therapies exist.
ConsumerLab, a medically reviewed testing publication, notes that BPC-157 cannot legally be sold in the U.S. as a dietary supplement ingredient and is not approved as a drug. Because compounding rules and committee outcomes can change, check the FDA’s compounding pages for the current status before relying on any summary, including this one.

Safety: what is known and what is not
The honest summary is that the safety profile is not established. Reviews cite no validated dosing, no long-term data and no large multicenter safety trials. The USADA, the U.S. anti-doping agency, states there is no known safe dose and no human clinical trials establishing efficacy for any diagnosis or treatment, and that its use may lead to adverse health effects.
The FDA’s concern about immunogenicity is a specific one. A peptide produced in an uncontrolled setting can contain impurities that provoke immune reactions, which is separate from any effect of the peptide itself.
Practical points for anyone weighing this topic:
- Tell a licensed clinician about any active or past cancer, pregnancy or breastfeeding, and every medication you take. Safety has not been studied in these groups, and clinicians reviewing the compound generally treat them as reasons to avoid it.
- Do not self-inject a vial of unknown origin. Reviewers note that online direct-to-consumer products cannot be assured of authenticity, purity, dose accuracy or freedom from contamination.
- Report unexplained symptoms after any injection (swelling, rash, fever, breathing difficulty) to a clinician promptly, and seek emergency care for severe reactions.
Tested athletes and servicemembers
The 2026 WADA Prohibited List, effective January 1, 2026, places BPC-157 under S0, non-approved substances, prohibited at all times, in and out of competition. S0 covers any pharmacological substance with no approval from a governmental health authority for human therapeutic use. The AANA also flags that peptide use can affect eligibility, readiness and career status for tested athletes and servicemembers. Fitness instructors and competitive amateurs who enter sanctioned events should check the rules of their governing body first.
Why the source and the prescriber matter
The AOSSM notes that BPC-157 belongs to a larger group of marketed injectable peptides, including TB-500, GHK-Cu and CJC-1295/ipamorelin, that share promising animal data without human efficacy evidence, and that online vendors have grown faster than the research. For a reader choosing how to access any peptide, the evidence question and the sourcing question are separate, and both need answers.
A research-chemical vendor typically offers no clinician review, no pharmacy of record, no prescription and no privacy obligations for your health information. A prescription pathway answers those points:
- A licensed provider reviews your history and decides whether a therapy is appropriate. Our guide on who prescribes peptides in the U.S. explains how state rules shape this.
- A licensed U.S. pharmacy prepares it for the individual patient. See what to verify in compounding pharmacy safety, and how 503A and 503B facilities differ.
- Health data is handled under HIPAA-compliant practices, which matters if privacy is a concern for you.
- Ongoing oversight means someone reviews your response and adjusts or stops treatment.
For a broader view of screening and side effects across the category, read peptide therapy safety: risks, side effects and screening.
Our perspective
We separate two questions that online marketing tends to merge: does a compound have human evidence, and is the way you obtain it safe and supervised?
For BPC-157, the first answer today is that human evidence is limited, and we do not describe any benefit the research has not shown. Our approach is to keep claims tied to what has been studied in people and to label preclinical findings as preclinical.
The second question is where a telehealth model helps. Every Vivo therapy follows a guided treatment selection process, is prescribed after provider review, is compounded by a licensed U.S. pharmacy and ships to the patient’s door, with HIPAA-compliant data practices throughout. People who might otherwise buy an unregulated vial online deserve a prescriber, a named pharmacy and a plan for follow-up.
Decisions are individual. A provider’s judgment about your history, medications and goals should set the plan, not a forum post or a vendor’s product page.
Jack
A supervised route with Vivo
Vivo offers provider-supervised therapies prescribed after review and compounded by licensed U.S. pharmacies, with HIPAA-compliant telehealth intake and delivery to your home. Current plans include Sermorelin at $135 per month, NAD+ nasal spray at $119 per month and MIC+B12 at $109 per month. Each is a separate therapy with its own evidence and its own provider review, so the right starting point is the product page for the specific therapy you are considering. For pricing across the category, see our 2026 peptide therapy cost guide.
Questions to ask any provider about a peptide
- Which specific compound, route and dose is being prescribed, and what human evidence supports it?
- Which licensed pharmacy compounds it, and in which state is it licensed?
- Who is the prescribing clinician, and are they licensed in my state?
- How is my health information stored and shared?
- Who reviews my response, and how do I stop treatment?
FAQ
Does BPC-157 work for tendon or joint injuries?
There is no adequate human evidence that it does. The only clinical study found in a 2025 systematic review was a case series of 12 knee-pain patients with no control group. Animal results have not been confirmed in controlled human trials.
Is BPC-157 legal and FDA-approved?
It is not FDA-approved. In July 2026 the FDA proposed that BPC-157 not be added to the 503A Bulks List, and it cannot legally be sold as a dietary supplement ingredient. Rules on compounding can change, so check the FDA’s current compounding pages.
Is BPC-157 banned in sports?
Yes. The 2026 WADA Prohibited List names it under S0, non-approved substances, banned at all times. Tested athletes and servicemembers risk their eligibility if they use it.
Who should avoid BPC-157?
Clinical reviews list active cancer, pregnancy and breastfeeding as situations to avoid it, because safety has not been studied there. No safe dose is established for anyone. A licensed clinician who knows your history and medications should guide any decision.
Sources
- Human evidence for BPC-157 in orthopaedic and regenerative medicine (PubMed, 2026)
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine (PubMed Central, 2025)
- Investigational Peptides in Orthopaedic Practice (PubMed, 2026)
- AANA Inside AANA newsletter, July 2026
- AOSSM Sports Medicine News: peptide injections
- FDA Pharmacy Compounding Advisory Committee briefing, July 23-24, 2026
- USADA: BPC-157 experimental peptide creates risk for athletes
- WADA 2026 Prohibited List
- ConsumerLab: BPC-157 and TB-500 uses and safety
- Evidence-first stem cell therapy for back pain
